Literature DB >> 7214787

Hemodynamic effects of morphine and nalbuphine in acute myocardial infarction.

G Lee, R I Low, E A Amsterdam, A N DeMaria, P W Huber, D T Mason.   

Abstract

Hemodynamic effects of morphine and the new narcotic analgesic, nalbuphine, were compared in a randomized, double-blind study in 15 patients with acute myocardial infarction (11 men and four women, average age 56.2 yr) and normal group mean hemodynamic function. During a 1-hr evaluation the hemodynamic effects were small but there were changes in several parameters. Morphine reduced heart rate (78 to 72 bpm, p less than 0.01) and diastolic and mean arterial pressures (69 to 64 mm Hg, p less than 0.05; and 91 to 84 mm Hg, p less than 0.05); nalbuphine was associated with a decrease in heart rate (82 to 72 bpm, p less than 0.01), decrease in cardiac index, which remained within the normal range (3.16 to 2.75 l/min/m(2), p less than 0.01), and an increase in systemic vascular resistance (1,204 to 1,461 dynes . sec . cm(-5), p less than 0.05). Neither drug altered systolic arterial pressure, pulmonary artery pressure, pulmonary capillary wedge pressure, stroke index, stroke work index, or pulmonary vascular resistance. Echocardiographic assessment revealed diminution of left ventricular mean velocity of circumferential fiber shortening after nalbuphine (1.26 to 1.08 circ/sec, p less than 0.05). Both drugs induced small reductions in respiratory rate and arterial pH and increases in PAO2. There were no changes in PaO2. Because of the absence of clinically important deleterious effects on cardiac pump function, nalbuphine merits further investigation as an analgesic in acute myocardial infarction.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7214787     DOI: 10.1038/clpt.1981.80

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  10 in total

Review 1.  Assessment and management of cardiovascular urgencies and emergencies: cognitive and technical considerations.

Authors:  D E Becker
Journal:  Anesth Prog       Date:  1988 Sep-Oct

2.  The pharmacokinetics of intravenous, intramuscular, and subcutaneous nalbuphine in healthy subjects.

Authors:  M W Lo; F H Lee; W L Schary; C C Whitney
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

3.  Case of morphine-induced ventricular fibrillation.

Authors:  Roman Skulec; Jitka Callerova; Jiri Knor; Petr Ostadal; Petr Kmonicek; Vladimir Cerny
Journal:  World J Emerg Med       Date:  2017

Review 4.  Opioid agonist-antagonist drugs in acute and chronic pain states.

Authors:  P J Hoskin; G W Hanks
Journal:  Drugs       Date:  1991-03       Impact factor: 9.546

5.  Plasma histamine and hemodynamic responses following administration of nalbuphine and morphine.

Authors:  S M Muldoon; M A Donlon; R Todd; E A Helgeson; W Freas
Journal:  Agents Actions       Date:  1984-10

6.  Experience with nalbuphine, a new opioid analgesic, in acute myocardial infarction.

Authors:  R A Greenbaum; G Kaye; P D Mason
Journal:  J R Soc Med       Date:  1987-07       Impact factor: 5.344

7.  A comparison of nalbuphine and meperidine in treatment of postoperative pain.

Authors:  E Hew; K Foster; R Gordon; E Hew-Sang
Journal:  Can J Anaesth       Date:  1987-09       Impact factor: 5.063

8.  [Treatment of acute gastrointestinal pain.].

Authors:  H Bierbach
Journal:  Schmerz       Date:  1993-09       Impact factor: 1.107

Review 9.  Nalbuphine. A preliminary review of its pharmacological properties and therapeutic efficacy.

Authors:  J K Errick; R C Heel
Journal:  Drugs       Date:  1983-09       Impact factor: 9.546

10.  Excessive morphine requirements after pre-hospital nalbuphine analgesia.

Authors:  K P Houlihan; R G Mitchell; A D Flapan; D J Steedman
Journal:  J Accid Emerg Med       Date:  1999-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.